Evaluation of Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction Treated With Warfarin or Reduced Dose Rivaroxaban
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Atrial fibrillation
- Focus Adverse reactions
- Acronyms CALLIPER
- Sponsors Bayer
- 17 Jan 2019 Planned End Date changed from 31 Dec 2018 to 30 Apr 2019.
- 17 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 30 Apr 2019.
- 04 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.